Science Webinar: Immunotherapy Meets Proteomics: A Winning Combination for Clinical Trial Success and Personalized Treatment? - Biognosys

Science Webinar: Immunotherapy Meets Proteomics: A Winning Combination for Clinical Trial Success and Personalized Treatment?

Available on-demand

Watch Now


Immunotherapy has transformed how cancer is treated and significantly improved patient outcomes. Yet the complexities of the cancer environment and the immune system’s interactions with cancerous cells are still poorly understood. As a result, clinical outcomes are unpredictable, necessitating a shift toward personalized treatments


This webinar will discuss results from an ongoing clinical trial in metastatic pancreatic cancer (mPC). The PRINCE trial utilizes a novel design and multiomics biomarker approach to investigate the activation of the immune system using combinations of chemotherapy, PD-1 blockade, and/or an experimental antibody that targets the CD40 protein. The webinar will conclude with an expert panel discussion about the pros and cons of different proteomics technologies for novel biomarker discovery, their applicability in immuno-oncology, and their transferability to clinical settings.


During the webinar, the expert panel will:

  • Provide novel insights into a known biomarker, CD40, and its role in activating the immune system against cancer
  • Demonstrate the application of a multiomics biomarker approach to monitoring pharmacodynamic markers
  • Take a deep dive into a novel, mass spectrometry–based plasma proteomics solution for unbiased discovery of clinically relevant biomarkers
  • Discuss integration of single-cell technologies—such as FACS (fluorescence-activated cell sorting) or CyTOF (cytometry by time of flight)—with population-level ‘omics, such as proteomics
  • Answer questions live during the broadcast.


This webinar will last for approximately 60 minutes.

Deena Maurer, Ph.D.
Parker Institute for Cancer Immunotherapy
San Francisco, CA



Dr. Maurer is a Translational and Regulatory Affairs Scientist Fellow in the Translational Medicine and Regulatory Affairs departments at the Parker Institute for Cancer Immunotherapy (PICI). She focuses on identifying and investigating biomarkers of response to anti-PD-1 treatment in the pancreatic cancer setting. Her work contributes directly to the PRINCE and REVOLUTION pancreatic platform studies. Prior to joining PICI, Dr. Maurer obtained her Ph.D. in microbiology and immunology from the University of Pittsburgh. She has also received her M.S. in biotechnology from Johns Hopkins University, completed a postbaccalaureate fellowship at the U.S. National Institutes of Health studying somatic mutations in endometrial cancer, and received her B.S. from Marywood University.

Diane Da Silva, Ph.D.
Parker Institute for Cancer Immunotherapy
San Francisco, CA



Dr. Da Silva is associate director of translational medicine at the Parker Institute for Cancer Immunotherapy (PICI). She directs the execution of the PICI translational suite of biomarker assays and contributes to disease- and immune-specific biomarker approaches in collaboration with PICI’s clinical and informatics teams. Prior to joining PICI, she was research faculty in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Keck School of Medicine of the University of Southern California (USC). She also served as the scientific director of the Beckman Center for Immune Monitoring at the USC Norris Comprehensive Cancer Center. Dr. Da Silva received her Ph.D. in cancer immunology and immunotherapy from Loyola University Chicago. She completed her National Cancer Institute postdoctoral training fellowship at USC, which focused on identifying mechanisms of viral and tumor immune evasion. She later obtained an M.S. in regulatory science from the USC School of Pharmacy with an emphasis on clinical trial research.

Marco Tognetti, Ph.D.
Schlieren, Switzerland



Dr. Tognetti is a principal scientist at Biognosys. He is leading the R&D development of novel sample-processing solutions to enable deep, robust, and scalable proteome profiling. Most notably, he has recently contributed to deep plasma profiling and immunopeptide enrichment approaches and has developed optimized and automated workflows for large-scale proteomics. Dr. Tognetti obtained his B.Sc., M.Sc., and Ph.D. from ETH Zurich. Before joining Biognosys in 2020, his research at ETH Zurich and the University of Zurich brought him to integrate multiomics approaches to improve drug response prediction in breast cancer.